Page last updated: 2024-12-05
malvalic acid
Description
malvalic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
malvalic acid : A long-chain cyclopropenyl fatty acid comprising 8-heptadecenoic acid having a cyclopropene ring arising from the linking of C-8 and C-9 by a methylene substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 10416 |
| CHEBI ID | 6673 |
| SCHEMBL ID | 25251 |
| MeSH ID | M0052049 |
Synonyms (24)
| Synonym |
|---|
| hsdb 3905 |
| 02ajq7vs2h , |
| unii-02ajq7vs2h |
| 1-cyclopropene-1-heptanoic acid, 2-octyl- |
| CHEBI:6673 |
| 2-octyl-1-cyclopropene-1-heptanoic acid |
| 7-(2-octylcycloprop-1-en-1-yl)heptanoic acid |
| 8,9-methylen-8-heptadecensaeure |
| malvalsaeure |
| LMFA01140002 |
| 8,9-methylene-8z-heptadecenoic acid |
| halphen acid |
| malvic acid |
| halphenic acid |
| malvalinic acid |
| 503-05-9 |
| malvalic acid |
| C08321 |
| 7-(2-octylcyclopropen-1-yl)heptanoic acid |
| 1-cyclopropene-1-heptanoicacid, 2-octyl- |
| SCHEMBL25251 |
| malvalic acid [hsdb] |
| DTXSID50198300 |
| Q412814 |
Drug Classes (3)
| Class | Description |
|---|
| cyclopropenyl fatty acid | Any fatty acid containing a three-membered carbocyclic unit which includes a double bond. |
| long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
| monounsaturated fatty acid | Any fatty acid with one double or triple bond in the fatty acid chain and singly bonded carbon atoms in the rest of the chain. MUFAs have positive effects on the cardiovascular system, and in diabetes treatment. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 25.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 25.78 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.39 (4.65) | | Search Engine Demand Index | 26.67 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |